Why Is Par Drugs and Chemicals Share Price Falling Key Reasons 2026

The Par Drugs and Chemicals share price falling trend has become a key investor concern in 2026. The stock has declined approximately 35 percent from its 52 week high of Rs 145 to current levels near Rs 95, prompting investors to ask whether this correction represents a buying opportunity or signals deeper structural challenges. Par Drugs and Chemicals (NSE: PAR), operating in the Pharmaceutical API and Chemicals space, has witnessed sustained selling pressure through FY26. Understanding the Par Drugs and Chemicals share price falling narrative requires careful analysis of both company-specific headwinds and the broader macro forces at work in 2026.

Click Here Get Free Investment Predictions

About Par Drugs and Chemicals

Pharmaceutical API and specialty chemicals manufacturer listed in 2021. Circuit range Rs 76 to Rs 113. Revenue Rs 100 crore. 52W high Rs 145, CMP Rs 95, down 35 percent. The stock is currently trading at approximately Rs 95, down 35 percent from its 52 week high of Rs 145. The 52 week low is Rs 76, and the market cap stands at approximately Rs 400 crore.

Parameter	Value
NSE Ticker	PAR
Sector	Pharmaceutical API and Chemicals
CMP (2026)	Rs 95
52 Week High	Rs 145
52 Week Low	Rs 76
Decline from 52W High	Approximately 35 percent
Market Cap	Rs 400 crore (approx)
Trailing P/E	20x

Why Is Par Drugs and Chemicals Share Price Falling: Key Reasons

1. FII Selling and Broad Market Correction

The dominant external driver behind the Par Drugs and Chemicals share price falling is the sustained FII selling wave that swept Indian equities through FY26. The US reciprocal tariff announcement imposing a 26 percent levy on Indian goods triggered a broad risk-off selloff, causing FIIs to pull significant capital from Indian equity markets. The 35 percent correction from the 52 week peak reflects the combined impact of macro-level FII selling and company-specific headwinds operating simultaneously in 2026.

2. Sector-Specific Headwinds in Pharmaceutical API and Chemicals

Beyond the broad market decline, the Pharmaceutical API and Chemicals sector faced its own challenges in FY26. Analyst earnings estimates were revised downward as input cost inflation, competitive pricing pressures and demand moderation weighed on sector outlook. This sector de-rating contributed meaningfully to the Par Drugs and Chemicals share price falling trend as institutional investors reduced overall sector exposure, leading to broad-based price declines across the peer group.

3. Earnings Deceleration and Margin Compression

A key company-specific factor behind the Par Drugs and Chemicals share price falling is the deceleration in earnings growth relative to the elevated expectations baked in at the 52 week high of Rs 145. Revenue and profitability came under pressure from input cost inflation, competitive pricing constraints and higher operating costs. The market is now recalibrating to a more moderate growth trajectory, triggering a meaningful re-rating from peak levels.

4. Valuation De-Rating from Peak Multiples

At its 52 week high of Rs 145, Par Drugs and Chemicals was trading at valuation multiples above its historical average. As quarterly results came in below peak expectations and sector sentiment turned cautious, the market applied lower multiples to the company’s earnings. This valuation de-rating from Rs 145 to Rs 95 is one of the primary mechanical drivers of the Par Drugs and Chemicals share price falling by 35 percent in 2026.

5. Small and Mid Cap Liquidity Squeeze

With a market cap of approximately Rs 400 crore, Par Drugs and Chemicals is exposed to the liquidity dynamics of the small and mid cap segment, which experienced a sharp squeeze in FY25-26. This liquidity effect has amplified the Par Drugs and Chemicals share price falling trend beyond what fundamentals alone would suggest, as thinner order books convert moderate selling into outsized price declines.

6. Global Macroeconomic Uncertainty

India’s equity market in FY26 faced macro headwinds including global tariff wars, crude oil price volatility and currency pressure, which collectively dampened institutional risk appetite. This macro overhang reinforced the Par Drugs and Chemicals share price falling pressure by keeping buyers cautious even when individual company fundamentals did not fully justify the magnitude of the sell-off.

Financial Performance Analysis of Par Drugs and Chemicals

The key metrics driving the Par Drugs and Chemicals share price falling narrative are visible across both quarterly earnings trends and valuation levels. The stock has fallen 35 percent from Rs 145 to Rs 95, with the market cap contracting to approximately Rs 400 crore. Investors should monitor upcoming results and management commentary on revenue recovery and margin trajectory as the primary near-term catalyst for any price stabilisation.

Key Metric	Current Level	52 Week Peak	Trend
Share Price	Rs 95	Rs 145	Down 35 percent
Market Cap	Rs 400 crore	Higher at 52W peak	Compressed
Trailing P/E	20x	Higher at 52W high	Multiple compressed
52 Week Range	Rs 76 to Rs 145

Screen Par Drugs and Chemicals and compare with sector peers on the Univest Screener.

Technical Signals What the Charts Are Saying

Technically, the stock is trading below its 50 day, 100 day and 200 day simple moving averages, all sloping downward. Since the 52 week high of Rs 145, Par Drugs and Chemicals has formed a clear pattern of lower highs and lower lows. Key support is at the 52 week low of Rs 76, while overhead resistance sits at the Rs 145 zone. Download the Univest iOS App or Univest Android App to track live price and get daily expert stock picks.

Can Par Drugs and Chemicals Share Price Recover

Despite the headwinds driving the Par Drugs and Chemicals share price falling trend, genuine recovery catalysts exist. Any positive inflection in the Pharmaceutical API and Chemicals sector driven by improved macro conditions or policy support could trigger a sharp re-rating. A quarterly earnings result beating the now-lowered analyst expectations could catalyse a short-covering rally from oversold levels. A broader recovery in small and mid cap market sentiment as FII flows normalise post the tariff shock would lift Par Drugs and Chemicals alongside the broader peer group. At Rs 95, a significant portion of the bad news may already be priced in, creating a potentially attractive entry point for investors with a 2 to 3 year horizon. The risk-reward for the Par Drugs and Chemicals share price falling thesis may be increasingly asymmetric in favour of patient long-term buyers.

Conclusion

The Par Drugs and Chemicals share price falling by approximately 35 percent from Rs 145 to Rs 95 reflects broad market headwinds, FII selling, earnings deceleration and valuation de-rating in the Pharmaceutical API and Chemicals sector. A sustainable reversal will require a clear improvement in quarterly financial momentum and a more constructive macro environment. Investors tracking the Par Drugs and Chemicals share price falling trend should monitor upcoming earnings results, any shifts in FII ownership and macro developments closely before making any fresh position decisions. For real-time data on Par Drugs and Chemicals, visit Univest.

Disclaimer Note: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Data sourced from publicly available open sources. SEBI Registration No. INH000013776.

Frequently Asked Questions

Why is Par Drugs and Chemicals share price falling in 2026?

Ans. The Par Drugs and Chemicals share price falling trend in 2026 is driven by FII selling following the US tariff announcement, sector headwinds in the Pharmaceutical API and Chemicals space, earnings deceleration and valuation de-rating. The stock has declined approximately 35% from its 52 week high of Rs 145 to the current Rs 95.

What is the 52 week high and low of Par Drugs and Chemicals?

Ans. The 52 week high of Par Drugs and Chemicals is Rs 145 and the 52 week low is Rs 76. The current price of approximately Rs 95 represents a decline of about 35% from the 52 week high.

Should I buy Par Drugs and Chemicals shares at current levels?

Ans. Whether to invest in Par Drugs and Chemicals at Rs 95 depends on your investment horizon and risk appetite. The stock has corrected 35% from its peak. Always consult a SEBI registered financial advisor before making any investment decision.

What are the recovery triggers for Par Drugs and Chemicals share price falling?

Ans. Key recovery catalysts for Par Drugs and Chemicals include quarterly earnings beating reduced analyst expectations, reversal of FII selling as global macro conditions improve, positive sector re-rating in the Pharmaceutical API and Chemicals space and a broader Indian market recovery.

What are the key downside risks to Par Drugs and Chemicals share price falling?

Ans. Key risks include continued earnings estimate downgrades, further FII selling, unexpected regulatory or competitive developments in the Pharmaceutical API and Chemicals sector and a deeper correction pushing the stock toward its 52 week low of Rs 76.

What is the market cap of Par Drugs and Chemicals?

Ans. The current market capitalisation of Par Drugs and Chemicals is approximately Rs 400 crore based on the prevailing price of Rs 95. This represents a significant compression from peak levels as the Par Drugs and Chemicals share price falling trend has persisted through 2026.